Crown Bioscience Expands Genomics and Next Generation Sequencing (NGS) Capabilities To Streamline Translational Biomarker Discovery Workflows
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"With our range of validated services, we can help drug developers improve the accuracy, sensitivity and speed at which they progress their new agent programs via discovery of MOAs and predictive biomarkers," said Henry Li, PhD, chief scientific officer at CrownBio. "This type of multi-omics data is essential to understand the clinical populations that respond to anticancer agents and progress cancer treatments."
"Quality downstream applications are key to maximizing the full potential of in vivo study results, including our wealth of historical model and treatment data," said Sheng Guo, PhD, head of bioinformatics at CrownBio. "These are leveraged by a highly experienced team and a proprietary, published algorithm to provide important biomarker discovery and drug mechanism probing services."
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
SAN DIEGO -- Businesswire -- Crown Bioscience, a JSR Life Sciences company, today announced the expansion of their state-of-the-art NGS capabilities, together with the launch of proprietary NGS panel services, providing increased opportunities for pharmaceutical partners to better understand drug mechanisms of action (MOA) and to develop predictive biomarkers for their investigational drug candidates.
The newly built, comprehensive suite of NGS capabilities provides clients with a streamlined multi-omics workflow of high-quality services, enabling full genomic understanding, including global gene expression, mutations, and genomic structures. This is a significant addition to CrownBio’s current preclinical and translational services, allowing clients greater insight into disease mechanisms, drug MOAs, and responder patient populations, to ultimately accelerate successful development of effective therapies.
The expanded services have been established at the Company’s Center of Translational Science in Suzhou, China, to meet increased client demand for whole genome sequencing (WGS), including Illumina’s Novaseq 6000 and BGI’s MGISEQ-2000 second generation sequencing platform. PacBio’s third generation Sequel Ⅱ sequencing platform allows for high throughput, high accuracy long-read NGS, and Bionano’s Saphyr® Genome Imaging enables large structural variant analysis and genome mapping. Comprehensive data analysis pipelines have also been built, together offering highly sensitive genome assembly and discovery algorithms.
“With our range of validated services, we can help drug developers improve the accuracy, sensitivity and speed at which they progress their new agent programs via discovery of MOAs and predictive biomarkers,” said Henry Li, PhD, chief scientific officer at CrownBio. “This type of multi-omics data is essential to understand the clinical populations that respond to anticancer agents and progress cancer treatments.”
In addition to the validated commercial platforms, CrownBio has also developed various powerful biomedical applications using NGS platforms, including NGS panels for bio-sample authentication, contamination detection and quantification, mouse tumor microenvironment profiling and metagenomic sequencing services for microbiome analysis. Custom NGS services are also available for clients who wish to utilize CrownBio’s expertise and large model biobank.
“Quality downstream applications are key to maximizing the full potential of in vivo study results, including our wealth of historical model and treatment data,” said Sheng Guo, PhD, head of bioinformatics at CrownBio. “These are leveraged by a highly experienced team and a proprietary, published algorithm to provide important biomarker discovery and drug mechanism probing services.”
These NGS services are available for client use immediately including our newly launched mouse I/O profiling targeted RNA-seq panel. The panel will allow deep profiling of the immunogenomics of murine tumor-immune interactions through the measurement of 1080 transcripts from a single sample.
About Crown Bioscience Inc.
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit:
· https://www.crownbio.com · https://www.jsrlifesciences.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210110005013/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Crown Bioscience Inc.
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 삼일제약, 임원 승진 인사 단행 - 뉴스와이어
- 빛의 시어터, 크리스마스 및 새해 맞이해 오는 31일까지 심야 특별전 운영 - 뉴스와이어
- ‘챗GPT 국내 일자리 10% 채운다’ 슈퍼코딩, AI 100% 취업 연계 교육프로그램 론칭 - 뉴스와이어
- EBS ‘특집 다큐 - 한국에서 세계로, 인도주의의 길’ 2부작 방영 - 뉴스와이어
- LG에너지솔루션, 7.5GWh 규모 ESS 프로젝트 공급계약 체결 - 뉴스와이어
- 효성중공업, 수소발전 시장 공략 - 뉴스와이어
- 현대자동차 ‘디 올 뉴 팰리세이드’ 사전계약 개시 - 뉴스와이어
- 한화그룹, 미국 필리조선소 인수 최종 완료 - 뉴스와이어
- LG생활건강, 강아지 발씻자 ‘티슈형’ 출시로 차별적 고객가치 제공 - 뉴스와이어
- 호텔 라마다 속초, 크리스마스 & 연말 맞이 디너 뷔페 및 다양한 이벤트 진행 - 뉴스와이어